Cargando…
Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a meta-analysis of randomized controlled trials
BACKGROUND/AIMS: The aim of this study was to assess the efficacy and safety of tofacitinib (5 and 10 mg twice daily) in patients with active rheumatoid arthritis (RA). METHODS: A systematic review of randomized controlled trials (RCTs) that examined the efficacy and safety of tofacitinib in patient...
Autores principales: | Song, Gwan Gyu, Bae, Sang-Cheol, Lee, Young Ho |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4164730/ https://www.ncbi.nlm.nih.gov/pubmed/25228842 http://dx.doi.org/10.3904/kjim.2014.29.5.656 |
Ejemplares similares
-
Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016) -
Tofacitinib 5 mg Twice Daily in Patients with Rheumatoid Arthritis and Inadequate Response to Disease-Modifying Antirheumatic Drugs: A Comprehensive Review of Phase 3 Efficacy and Safety
por: Bird, Paul, et al.
Publicado: (2019) -
Erratum: Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biologic diseasemodifying antirheumatic drugs
Publicado: (2017) -
Indirect Treatment Comparison of the Efficacy and Safety of Sarilumab Monotherapy in Rheumatoid Arthritis Patients with Inadequate Response to Conventional Disease-Modifying Antirheumatic Drugs
por: Choy, Ernest, et al.
Publicado: (2019) -
Switching and Discontinuation Pattern of Biologic Disease-Modifying Antirheumatic Drugs and Tofacitinib for Patients With Rheumatoid Arthritis in Taiwan
por: Li, Ko-Jen, et al.
Publicado: (2021)